NEW YORK (360Dx) – Australian proteomics firm Proteomics International (PILL) presented validation data at this week's American Diabetes Association annual meeting in San Diego that indicates its PromarkerD test could be helpful in identifying patients at risk of developing diabetic kidney disease.

In a prospective clinical study following 792 type 2 diabetes patients over four years, the company found that the test could identify patients who would develop kidney disease within that time period with a sensitivity of 86 percent and a specificity of 78 percent.